Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by ANALIAS00on Feb 24, 2021 2:21pm
96 Views
Post# 32648869

RE:RE:Technicals

RE:RE:TechnicalsI agree but this stock became so speculative after realising that Trogarzo market expectations were far from what is was expected at some point. That stock will remain very fragile.

About tomorrow I wish there will be good news but it is the case, those certainly not new for TH. And if TH's management are so confident about the future and have good news for shareholders that can increase investors's confident, same question comes again: why were they not able to sign a better deal for them and for us shareholders ? All they might give us tomorry is hope based on what we already know so far. They are just doing the same thing as any other biotech that are trying to convince their shareholders and future investors that they have something promising in their hands. Nothing more, nothing less. Phase I results may or may not confirm that. Just sad for us that no one are willing to speculate on TH at this moment. But if no one of us are willing to sell until phase I results are out, that makes any difference that SP is at $3.60(can) or $5.00(can).
ggg088 wrote: If any good news can be released from tomorrow morning conference , I think the 3 dollar will be the new support level.


<< Previous
Bullboard Posts
Next >>